- Home
- ATLX vs BDTX Comparison
ATLX vs BDTX Comparison
Compare ATLX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATLX | BDTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 116.8M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATLX | BDTX |
|---|---|---|
| Price | $4.43 | $2.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $10.20 |
| AVG Volume (30 Days) | 322.0K | ★ 573.8K |
| Earning Date | 05-08-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.08 | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | N/A |
| P/E Ratio | ★ N/A | $5.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $1.20 |
| 52 Week High | $8.25 | $4.94 |
Technical Indicators
Market Signals| Indicator | ATLX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 56.13 |
| Support Level | $4.32 | $2.20 |
| Resistance Level | $5.25 | $2.86 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 36.82 | 89.47 |
Price Performance
Historical ComparisonAbout ATLX Atlas Lithium Corporation
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.